Právní předpis byl sestaven k datu 19.12.2013.
Zobrazené znění právního předpisu je účinné od 25.12.2012 do 19.12.2013.
97
XXXXXXX
Xxxxxxxxxxxx xxxxxxxxxxxx xxxx,
xxxxxx xx xxxx x xxxxxxxx sdělení Xxxxxxxxxxxx xxxxxxxxxxxx věcí x. 58/2007 Xx. x. x., č. 46/2008 Xx. x. x. x x. 47/2012 Sb. x. x. x Xxxxxxxxxxx xxxxxx proti xxxxxxx xx xxxxxx
Xxxxxxxxxxxx xxxxxxxxxxxx xxxx xxxxxxx, že xxx 16. xxxxxxxxx 2011 xxxx generální ředitelkou XXXXXX xxxxxxxx xxxxxxxxx xxxxxx znění Xxxxxxx X - Xxxxxxx xxxxxxxxxx látek a xxxxx - Xxxxxxxxxxx xxxxxxxx Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx xx xxxxxx.1)
X xxxxx xxxxxx Xxxxxxx X xxxxxxxx xxxxxxx Xxxxxxxxx Xxxxx xxxxxxxxx.
Xxxx xxxxx Xxxxxxx X xxxxxxxxx x platnost x xxxxxxx x xxxxxxx 34 xxxx. 3 Xxxxxx xxx 1. ledna 2012 x xxxxx xxxx xxxxxxxxx v xxxxxxxx x xxx Českou xxxxxxxxx. Xxxx xxxxxx xxxxxx znění Přílohy X v platnost xxxxxxxx xxxxxx xxxxx Xxxxxxx X Mezinárodní xxxxxx proti dopingu xx sportu platné xx 1. ledna 2011 x xxxxxxxxx xxx č. 47/2012 Sb. m. s.
Xxxxxxxx xxxxx Xxxxxxx X x její překlad xx xxxxxxx xxxxxx xx xxxxxxxxx současně.
1) Mezinárodní xxxxxx proti dopingu xx sportu xxxxxxx xxx 19. října 2005 x Xxxxxx xxxx xxxxxxxxx pod č. 58/2007 Sb. m. s.
XXXXXXXXXXX XXXXXX PROTI DOPINGU XX SPORTU
Xxxxxxx X - Xxxxxx xxxxxxxxxx látek x xxxxx - Xxxxxxxxxxx xxxxxxxx
Paříž, 1. xxxxx 2012
XXXXXX XXXXXXXXXX XXXXX X XXXXX XXXXXXX PRO XXX 2012
XXXXXXX XXXXXXXXXXXXX XXXXX
Xxxxxx xx 1. xxxxx 2012
Podle článku 4.2.2 Xxxxxxxxx antidopingového xxxxxx všechny Zakázané xxxxx xxxxx xxxxxxxxxx xx "Specifické látky" xxxxx xxxxx xx xxxxxx S1, S2, X4.4, S4.5 a X6(x) x Xxxxxxxxxx xxxxx M1, X2 x X3.
LÁTKY X METODY XXXXXXXX XXXXX (XXX XXXXXXX X MIMO XXXXXX) |
XXXXXXXX LÁTKY
S0. XXXXXXXXXXX XXXXX
Xxxxxxxxx xxxxxxxxxxxxx xxxxx, která xxxx zahrnuta v xxxxxxxxxxxxx xxxxxxx Xxxxxxx x není aktuálně xxxxxxxxx pro xxxxxxx xxxxxxxxxxxx použití jakýmkoliv xxxxxxx zdravotnickým xxxxxxxxxx xxxxxx (xxxx. xxxxxx x xxxxxxxxxxxx nebo xxxxxxxxx xxxxxx výzkumu xxxx po ukončené xxxxxxxxxx, xxxxxxxxxx drogy, xxxxxxxxxxx xxxx), je xxxxxxxx xxxxx.
X1. XXXXXXXXXX XXXXX
Xxxxxxxxxx xxxxx jsou xxxxxxxx.
1. XXXXXXXXXX XXXXXXXXXX XXXXXXXX (AAS):
(a) Xxxxxxxx* XXX, xxxxxxxxxx:
1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3β,17β-xxxx); 1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3,17-xxxx); bolandiol (xxxx-4-xx-3β,17β-xxxx); xxxxxxxxxx; xxxxxxxx; xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx); xxxxxxx (17α-xxxxxxx-17β-xxxxxxxxxxxxxx-4-xxx[2,3-x]xxxxxxxx); xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-chloro-17β-hydroxy-17α-methylandrosta-1,4-dien-3-on); xxxxxxxxxxxxxxxxxxxxxxx (17α-xxxxxx-5α-xxxxxxx-2-xx-17β-xx); xxxxxxxxxxx; xxxxxxxxxxxxx (19-xxx-17α-xxxxx-4-xx-17-xx); xxxxxxxxxxxxxx; formebolon; xxxxxxxxx (17β-hydroxy-17α-methyl-5α-androstano[2,3-c]-furazan); xxxxxxxxx; 4-xxxxxxxxxxxxxxxxxx (4,17β-xxxxxxxxxxxxxxxx-4-xx-3-xx); xxxxxxxxxx; xxxxxxxxx; mestanolon; xxxxxxxxxx; xxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx); metenolon; xxxxxxxxxxx; xxxxxxxxxx (2α, 17α-xxxxxxxx-5α-xxxxxxxxx-3-xx-17β-xx); xxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxx-4,9-xxxx-3-xx); xxxxxx-1-xxxxxxxxxxx (17β-hydroxy-17α-methyl-5α-androst-1-en-3-on); xxxxxxxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxx-4-xx-3-xx); xxxxxxxxxxxxxxxxx; xxxxxxxxxx (xxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxx-4,9,11-xxxxx-3-xx); xxxxxxxxx; xxxxxxxxx; 19-xxxxxxxxxxxxxxxx (estr-4-en-3,17-dion); xxxxxxxxxx; xxxxxxxxxxxxxx; norklostebol; xxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx (17β-xxxxxxx-5α-xxxxxxxxxx [3,2-x]xxxxxxx); xxxxxxxxx; xxxxxxxxxx; xxxxxxxxx; 1-xxxxxxxxxxx (17β-xxxxxxx-5α-xxxxxxx-1-xx-3-xx); xxxxxxxxxxxxxxxxxxx (18α-xxxx-xxxxxx-4,9,11-xxxxx-17β-xx-3-xx); trenbolon x xxxxx xxxxx x xxxxxxxx chemickou xxxxxxxxxx xxxx podobnými xxxxxxxxxxxx xxxxxx.
(x) Xxxxxxxxx** XXX, pokud xxxx xxxxxx exogenně:
Xxxxxxxxxxxxx (xxxxxxx-5-xx-3β,17β-xxxx), xxxxxxxxxxxxx (xxxxxxx-4-xx-3,17-xxxx), dihydrotestosteron, xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, XXXX), xxxxxxxxxxx x xxxxxx metabolity x isomery, ale xx x omezením xxxxx xx ně:
5α-xxxxxxxxx-3α,17α-xxxx | 5-androstendion (xxxxxxx-5-xx-3,17-xxxx) |
5α-xxxxxxxxx-3α,17β-xxxx | |
5α-xxxxxxxxx-3β,17α-xxxx | xxx-xxxxxxxxxxxxxxxxxx |
5α-androstan-3β,17β-diol | epitestosteron |
xxxxxxx-4-xx-3α,17α-xxxx | 3α-hydroxy-5αandrostan-17-on |
androst-4-en-3α,17β-diol | 3β-xxxxxxx-5αxxxxxxxxx-17-xx |
xxxxxxx-5-xx-3β,17α-xxxx | 7α-xxxxxxx-XXXX |
xxxxxxx-5-xx-3α,17α-xxxx | 7β-xxxxxxx-XXXX |
androst-5-en-3α,17β-dioI | 7-xxxx-XXXX |
xxxxxxx-5-xx-3β,17α-xxxx | 19-xxxxxxxxxxxxxx |
4-xxxxxxxxxxxxx (xxxxxxx-4-xx-3β,17β-xxxx) | 19-noretiocholanolon |
2. Xxxxxxx xxxxxxxxxx xxxxx, xxxxxxxxxx:
Klenbuterol, xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (XXXX), xxxxxxx, xxxxxxx, xxxxxxxxxx, xxx xx x xxxxxxxx xxxxx xx xx.
Xxx účely xxxxxxx xxxx xxxxx: * "xxxxxxxx" xx xxxxxxxx x xxxxx, xxxxxx xxxx xxxx normálně xxxxxxx xxxxxxxxxx xxxxxxxxx. ** "xxxxxxxxx " xx xxxxxxxx k xxxxx, xxxxxx xxxx xxxx produkovat xxxxxxxxx. |
S2. XXXXXXXXX XXXXXXX, RŮSTOVÉ XXXXXXX X PŘÍBUZNÉ LÁTKY
Xxxxxxxxxxx látky x xxxxxx xxxxxxxxxx faktory xxxx zakázány:
1. Xxxxx stimulující xxxxxxxxxxx (xxxx. xxxxxxxxxxxx (XXX), xxxxxxxxxxx (xXXX), xxxxxxxxxxxxx xxxxxxx xxxxxxxxxxxxxx faktoru (XXX), xxxxxxxxxxxxxxxxxxxxxxxx-xxxxxxx beta (XXXX), xxxxxxxxxxx /Hematide/);
2. Xxxxxxxxxxxxxxxxxx (XX) x Iuteinizační xxxxxx (XX) u xxxx;
3. Insuliny;
4. Xxxxxxxxxxxxxx;
5. Růstový xxxxxx (XX), xxxxxxxxxxxxx xxxxxxx faktory (XXXx), xxxxxxxxxxxx xxxxxxx xxxxxx (XXX), xxxxxxxx xxxxxxx xxxxxxx xxxxxx-1 (IGF-1), xxxxxxxxxx růstové faktory (XXX), růstový faktor xxxxxxxx x xxxxxxxx xxxxxxxx (PDGF) x xxxxxxxxxx-xxxxxxxxxxxx xxxxxxx xxxxxx (XXXX), xxxxxx xxxx xxxxxxxxx xxxx xxxxxxx xxxxxxx xxxxxxxxxxx xxxxxxx xxxx xxxxxxxxx xxxxxxxx xxxxx, xxxxx x xxxxxx, xxxxxx xxxxxxxx, xxxxxxx energie, xxxxxxxxxxxxx xxxxxxxx xxxx xxxxxxxxxxx xxxx xxxxxxxxx xxxxxx;
x další xxxxx x podobnou chemickou xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx účinky.
X3. XXXX2- AGONISTÉ
Xxxxxxx xxxx-2 xxxxxxxx (xxxxxx xxxx xxxxxxxxxx xxxxxxxxx xxxxxxx) xxxx xxxxxxxx xxxxx xxxxxxxxxxx (xxxxxxxxx 1600 mikrogramů xx 24 xxxxx), formoterolu (xxxxxxxxx 36 xxxxxxxxxx xx 24 xxxxx) x xxxxxxxxxxx xxxxx xxxx xxxxxx x xxxxxxxx x souladu x xxxxxxxxxxx xxxxxxxx xxxxxxx xxxxxxx.
Xxxxxxxxxx xxxxxxxxxxx x moči x xxxxxxxxxxx vyšší xxx 1000 xx/xx x přítomnost formoterolu x moči v xxxxxxxxxxx xxxxx než 30 xx/xx xxxxxx xxxxxxxxxx xx xxxxxxxxx xxxxxxxxxxxx xxxxxxx, ale xxxx xxxxxxxxxx xx xxxxxxxxx xxxxxxxxxxx xxxxx, xxxxx xxxxxxxxx xxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxxxxxx xxxxxx, xx abnormální xxxxxxxx xxx způsoben xxxxxxxx xxxxxxxxxxxx xxxxxxxxx xxxxx xxxxx než xxxx xxxxxxx xxxxxxx.
S4. XXXXXXXXX X XXXXXXXXXXX XXXXXXXXXX
Zakázané xx xxxxxxxxxxx:
1. Inhibitory xxxxxxxx, xxxxxxxxxx:
Xxxxxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxx-1,4,6-xxxxx-3-17-xxxx (androstatriendion), 4-xxxxxxxxx-3,6,17-xxxxx (6-xxx),xxxxxxxxx, xxxxxxxxx, xxxxxxxx, xxxxxxxxxxx, xxx xx x omezením xxxxx xx ně.
2. Selektivní xxxxxxxxxx xxxxxxxxxxxxx receptorů (XXXX), xxxxxxxxxx:
Raloxifen, tamoxifen, xxxxxxxxx, ale ne x xxxxxxxx xxxxx xx xx.
3. Xxxxxxx xxxxxxxxxxxxxx xxxxx xxxxxxxxxx:
Xxxxxxxxxx, fulvestrant, xxxxxxxx, xxx ne x omezením xxxxx xx ně.
4. Xxxxx xxxxxxxxxxxx funkce xxxxxxxxxx včetně inhibitorů xxxxxxxxxx, xxx xx x xxxxxxxx pouze xx xx.
5. Xxxxxxxxxxx xxxxxxxxxx: Xxxxxxxx xxxxx xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxxxxxx /Xxxxxxxxxx Xxxxxxxxxxxx Xxxxxxxxx Xxxxxxxx δ (PPARδ) agonists/ (xxxx. XX 1516) x Xxxxxxxx xxxxxxxxxxxxxxx xxx aktivované XXX x xxxxxxxxxxx s XXXX xxxxx /XXXXδ-XXX-xxxxxxxxx xxxxxxx kinase (XXXX) xxxx agonists/ (xxxx. XXXXX)
S5. DIURETIKA X XXXXXXX MASKOVACÍ XXXXX
Xxxxxxxxx látky xxxx xxxxxxxx. Xxxxxxxx:
Xxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxxxxxxx (xxxx. xxxxxxxx, xxxxxxxxxx xxxxxx xxxxxxxx, dextranu, xxxxxxxxxxxxxxxxxx a xxxxxxxxx), xxxxxxxxxx x další xxxxx x podobnými xxxxxxxxxxxx účinky. Xxxxxxx xxxxxxxx xxxxxxxxxxxx pro xxxxx xxxxxxxx xxxx xxxxxxxx.
Xxxxxxxxx zahrnují:
Xxxxxxxxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxx, indapamid, xxxxxxxx, xxxxxxxx xxxxxxxxxx, xxxxxxxxx, spironolakton, xxxxxxxx (xxxx. bendroflumethiazid, xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx), xxxxxxxxxx x xxxxx látky x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx (xxxxx xxxxxxxxxxxx, xxxxxxxxx a xxxxxxxxx xxxxxx xxxxxxxxxxx a xxxxxxxxxxxx, které xxxxxx xxxxxxxx).
Pro xxxxxxx (Xxx Xxxxxxx, případně Xxxx Xxxxxx) xxxxxxxxxxx xxxxxxxx xxxxx xx xxxxxxxxxx xxxxxxxx xxxxxxx (xx. formoterol, salbutamol, xxxxxx, xxxxx, xxxxxxx, xxxxxxxxxxxx a xxxxxxxxxxxxx) xx spojení s xxxxxxxxxx xxxx xxxxx xxxxxxxxx xxxxxx xx xxxxxxxxxx udělení xxxxxxxxxx Xxxxxxxxxxxx xxxxxxx na xxxx látku xxxxx x té, která xxx xxxx xxxxxxx xx diuretikum nebo xxxxx xxxxxxxxx látku.
XXXXXXXX METODY
M1. XXXXXXXXX XXXXXXX XXXXXXX
Xxxxxxxx xx následující:
1. Krevní xxxxxx, xxxxxx xxxxxxx xxxxxxxxx, xxxxxxxxx xxxx xxxxxxxxxxx xxxx nebo xxxxxxxxx xxxxxxx x xxx xxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxx.
2. Xxxxx xxxxxxxxx spotřeby, xxxxxxx xxxx xxxxxxx xxxxxxx, xxxxxxxxxx xxxxxxxxxxxx hemoglobinové xxxxxxxx (např.krevní náhražky xxxxxxxx na hemoglobinu, xxxxxxxxxxxxxxxxxx xxxxxxxxxxx), xxxxxxxxxxxxxxxxxxx x xxxxxxxxxxx (XXX13), xxx ne s xxxxxxxx pouze na xx. Xxxxxxxx kyslíku xxxxxxxx xxxx.
X2. XXXXXXXX X FYZIKÁLNÍ XXXXXXXXXX
Zakázané xx xxxxxxxxxxx:
1. Xxxxxxxxx, xxxx pokus x xxxxxx, za xxxxxx xxxxxxx integritu a xxxxxxxx Xxxxxx xxxxxxxxxx xxx Xxxxxxxxx xxxxxxxx xx xxxxxxxx. To xxxxxxxx xxxxxx x/xxxx xxxxxx (např. xxxxxxxxxx) xxxx, ale xx x omezením pouze xx ně.
2. Xxxxxxxxxx infuze x/xxxx xxxxxxx více xxx 50 xx xx 6 xxxxx jsou xxxxxxxx xxxxx infuzí xxxxxxxxx přijatých x xxxxxxx xxxxxxxxxxxx zákroků xxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxx.
3. Xxxxxxxx xxxxx, xxxxxxxxxx x xxxxxxxxx xxxxxxxxxxx množství xxxx xxxx do xxxxxxxxx systému xx xxxxxxxx.
X3. XXXXXX XXXXXX
X xxxxxx xxxxxxxxxx xx zvýšení xxxxxxxxxxx xxxxxx xx xxxxxxxx xxxxxxxxxxx:
1. Xxxxxxxx nukleových xxxxxxx xxxx jejich xxxxxxxx;
2. Použití xxxxxxxxxx xxxx geneticky modifikovaných xxxxx;
XXXXX X XXXXXX ZAKÁZANÉ XXX SOUTĚŽI |
Xxxxx xxxxxxxxx XX xx S5 a X1 xx X3 xxxxxxxxx výše xxxx Xxx Xxxxxxx zakázané x xxxxxxxxxxx xxxxxxx:
XXXXXXXX LÁTKY
X6. XXXXXXXXXXX
Xxxxxxx stimulancia (xxxxxx xxxx xxxxxx xxxxxxxxxx optických isomerů) xxxx xxxxxxxx, s xxxxxxxx derivátů xxxxxxxxx x xxxxxxx xxxxxx xxxxxxxx xxxxxxx x xxxxxxxxxxx xxxxxxxxxx do Xxxxxxxxxxxxxx programu xxx xxx 2012*.
Stimulancia xxxxxxxx:
(a) Xxxxxxxxxxxx xxxxxxxxxxx:
Adrafinil, amfepramon, xxxxxxxxxxx, amfetamin, amifenazol, xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxxxx, xxxxxxxxx, dimethylamfetamin, xxxxxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxx, fenetylin, xxxxxxxxxxx, fenkamin, fenmetrazin, xxxxxxxxxxx, xxxxxxxxx, 4-xxxxxxxxxxxxxx (xxxxxxxx), xxxxxxxxxx, xxxxxxxxxxx, xxxxxx, xxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, mefentermin, xxxxxxxxxxxx (x-), xxxxxxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxxxxxxxxx, xxxxxxxx, xxxxxxxxx, norfenfluramin, x-xxxxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxx.
Xxxxxxxxxxxx, které xxxx xxxxxxxx xxxxxxx v xxxxx odstavci, xx Xxxxxxxxxxx látkou.
(x) Xxxxxxxxxx stimulancia (xxxxxxxx):
Xxxxxxxxx**, katin***, xxxxxxx****, xxxxxxxx, etilefrin, xxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxx, heptaminol, xxxxxxxxxxxx, levmetamfetamin, xxxxxxxxxxxx, xxxxxxxxxxxx****, methylfenidát, xxxxxxxxxxxxxxx (xxxxxxxxxxxxxxxxx), xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, xxxxxxxxx, parahydroxyamfetamin, xxxxxxx, pentetrazol, propylhexedrin, xxxxxxxxxxxxx*****xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxx x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx biologickými xxxxxx.
* Následující xxxxx xxxxxxxx xx Xxxxxxxxxxxxxx xxxxxxxx 2012 (xxxxxxxxx, xxxxxxxxxx, fenylpropanolamin, kofein, xxxxxxx, xxxxxxxxx, xxxxxxxx) xxxxxx xxxxxxxxxx za Xxxxxxxx xxxxx.
** Xxxxxxx podání adrenalinu (xxxx. nosní, oční xxxxxxxx) nebo jeho xxxxxx společně x xxxxxxxxx anestetiky xxxx xxxxxxxx.
*** Xxxxx xx zakázaný pouze xxx koncentraci xxxxx xxx 5 xxxxxxxxxx x 1 xx xxxx.
**** Xxxxxxx x xxxxxxxxxxxxx jsou xxxxxxxx xxx xxxxxxxxxxx xxxxx xxx 10 xxxxxxxxxx x 1 xx moči.
***** Xxxxxxxxxxxxx je xxxxxxx, xxxxx xxxx xxxxxxxxxxx x xxxx je xxxxx xxx 150 xxxxxxxxxx na xxxxxxxx
X7. XXXXXXXXX
Xxxxxxxx xx xxxxxxxxxxx:
Buprenorfin, xxxxxxxxxxxxx, xxxxxxxxx(xxxxxx), xxxxxxxx x jeho xxxxxxxx, xxxxxxxxxxx, xxxxxxx, xxxxxx, xxxxxxxx, oxymorfon, pentazocin, xxxxxxx.
X8. XXXXXXXXXXX
Xxxxxxxx (např. hašiš, xxxxxx a xxxxxxxxx) xxxx syntetický xxxxx9xxxxxxxxxxxxxxxxxxx (XXX) x xxxxxxxxxxxxxx (xxxx. "Xxxxx" /obsahující XXX018, XXX073/ a XX-210) xxxx xxxxxxxx.
X9. GLUKOKORTIKOSTEROIDY
Všechny xxxxxxxxxxxxxxxxxxxx xxxxxxxx orálně, xxxxxxxx, xxxxxxxxxx nebo xxxxxxxxxxxxx xxxxxxxx xxxx xxxxxxxx.
XXXXX XXXXXXXX V XXXXXXXX XXXXXXXX |
X1. XXXXXXX
Xxxxxxx (xxxxxx) xx zakázaný xxxxx Xxx Xxxxxxx v xxxxxxxxxxxxx sportech. Detekce xx xxxx provádět xxxxxxxx xxxxxxxx x/xxxx xxxxxxxx krve. Prahová xxxxxxx pro porušeni xxxxxxxxxxx xxxxxxxx (xxxxxxxxxxxxx xxxxxxx) je 0.10 x/x.
∙ Xxxxxxxxxxxx xxxxx (XXX)
∙ Xxxxxx (XXX)
∙ Xxxxxxx xxxxxx x xxxxxxxxxxxx(XXX)
∙ Xxxxxxxxxxx (XXXX)
∙ Motocyklový xxxxx (XXX)
∙ Xxxxx xxxxxxxxxx (XXX)
X2. XXXX-XXXXXXXXX
Pokud xxxx xxxxx určeno, xxxx-xxxxxxxxx jsou xxxxxxxx xxxxx Xxx Xxxxxxx x xxxxxxxxxxxxx xxxxxxxx.
∙ Automobilový xxxxx (XXX)
∙ Xxxxxxxx (xxxxxxx xxxxxxxxxx) (XXXX)
∙ Bridž (XXX)
∙ Xxxx (IGF)
∙ Xxxxxxx x xxxxxxx (XXX)
∙ Xxxxxxx sporty x xxxxxxxxxxxx (XXX)
∙ Xxxxxxxxxxx (FITA, XXX) (xxxxxxxx xxxx Xxxx xxxxxx)
∙ Xxxxxxxx (XXX) - xxxxx xx xxxxxx x xxxxxxxxxxx lyžování-skoky x X-xxxxx,x xxxxxxxxx X-xxxxx x "xxx air"
∙ Xxxxxxxx x xxxxxxx xxxxxx (CMSB)
∙ Xxxxxxx (ISSF, XXX) (xxxxxxxx také Xxxx xxxxxx)
∙ Xxxxx (XXX)
∙ Xxxxx xxxxxxxxxx (XxX)
Xxxx-xxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxx:
Xxxxxxxxxx, xxxxxxxxxx, xxxxxxxx, betaxolol, bisoprolol, xxxxxxx, celiprolol, esmolol, xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxx, metoprolol, xxxxxxx, oxprenolol, pindolol, xxxxxxxxxxx, xxxxxxx, xxxxxxx, xxx xx s xxxxxxxx xxxxx xx xx.
Xxxxxxxxx
Xxxxxx xxxxxxx x. 97/2012 Xx. m. x. xxxxx xxxxxxxxx xxxx 25.12.2012.
Xxxxxx xxxxxxx x. 97/2012 Xx. m. x. byl xxxxxx xxxxxxx xxxxxxxxx č. 98/2013 Sb. m. s. x účinností xx 20.12.2013.
Xxxxx xxxxxxxxxxxx právních xxxxx xxxxxx xxxxxxxx xxxxxxxx x xxxxxxxx xxxx xxxxxxxxxxxxx, xxxxx xx xxxx xxxxxx derogační xxxxx xxxxx xxxxxxxxx xxxxxxxx xxxxxxxx.